← back to search

Mark G. Swain

Newcastle University · CA
Area of research
Hepatology · Astronomy and Astrophysics
Research interest
Research interests include Stellar, planetary, and galactic studies, Liver Disease Diagnosis and Treatment, Liver Diseases and Immunity, and Astronomy and Astrophysical Research.
h-index
72
citations
19,306
works
604
NIH funding
primary concept
Medicine
email

Recent publications

Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways
JHEP Reports 2026cited by 1position: contributordoi
A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.
2025cited by 1position: contributordoi
The effects of elafibranor in people with primary biliary cholangitis: a plain language summary
Future Rare Diseases 2025cited by 1position: contributordoi
Assessment of fatigue and its impact in chronic liver disease.
2024cited by 30position: contributordoi
Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.
2024cited by 28position: contributordoi
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
2024cited by 25position: contributordoi
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
2024cited by 25position: contributordoi
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
JHEP Reports 2024cited by 13position: middledoi
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
JHEP Reports 2024cited by 12position: contributordoi
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
New England Journal of Medicine 2023cited by 245position: middledoi
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hepatology 2023cited by 109position: middledoi
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
2023cited by 85position: contributordoi
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Alimentary Pharmacology & Therapeutics 2023cited by 34position: middledoi
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial
Hepatology Communications 2023cited by 33position: middledoi
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial.
2023cited by 24position: contributordoi
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study.
2023cited by 7position: contributordoi
Featured Cover
Alimentary Pharmacology & Therapeutics 2023cited by 0position: contributordoi
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
˜The œLancet. Gastroenterology & hepatology 2022cited by 2,062position: middledoi
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
Journal of Hepatology 2022cited by 168position: middledoi
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Journal of Hepatology 2022cited by 78position: middledoi
A New Analysis of Eight Spitzer Phase Curves and Hot Jupiter Population Trends: Qatar-1b, Qatar-2b, WASP-52b, WASP-34b, and WASP-140b
The Astronomical Journal 2022cited by 36position: middledoi
A New Analysis of Eight Spitzer Phase Curves and Hot Jupiter Population Trends: Qatar-1b, Qatar-2b, WASP-52b, WASP-34b, and WASP-140b
The Astronomical Journal 2022cited by 35position: contributordoi
Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis
Gastroenterology 2021cited by 717position: middledoi
Detection of an Atmosphere on a Rocky Exoplanet
The Astronomical Journal 2021cited by 66position: contributordoi
Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996–2016
The American Journal of Gastroenterology 2021cited by 64position: middledoi
A comprehensive reanalysis of <i>Spitzer</i>’s 4.5 μm phase curves, and the phase variations of the ultra-hot Jupiters MASCARA-1b and KELT-16b
Monthly Notices of the Royal Astronomical Society 2021cited by 64position: middledoi
Disequilibrium Chemistry in Exoplanet Atmospheres Observed with the Hubble Space Telescope
The Astronomical Journal 2021cited by 33position: contributordoi
Characterization of an Instrument Model for Exoplanet Transit Spectrum Estimation through Wide-scale Analysis on HST Data
The Astronomical Journal 2021cited by 4position: contributordoi
Utilizing Small Telescopes Operated by Citizen Scientists for Transiting Exoplanet Follow-up
Publications of the Astronomical Society of the Pacific 2020cited by 47position: contributordoi
The Evolutionary Track of H/He Envelopes of the Observed Population of Sub-Neptunes and Super-Earths
The Astrophysical Journal 2020cited by 8position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 14 papers (2019–2026)Abdel Aziz Shaheen · Western University6 papers (2018–2026)Robert T. Zellem · Goddard Space Flight Center5 papers (2019–2022)Gael M. Roudier · Jet Propulsion Laboratory5 papers (2019–2021)Raissa Estrela · Jet Propulsion Laboratory4 papers (2020–2021)Gilaad G. Kaplan · Mount Sinai Hospital4 papers (2018–2023)Gideon M. Hirschfield · University Health Network4 papers (2019–2024)Christopher L. Bowlus · Washington State University4 papers (2022–2025)David Jones · Newcastle upon Tyne Hospital3 papers (2023–2023)Marlyn J. Mayo · Center for Digestive and Liver Diseases3 papers (2022–2025)Nikole K. Lewis · Cornell University3 papers (2015–2022)Cynthia Levy · University of Miami3 papers (2022–2023)Andreas E. Kremer · University of Zurich3 papers (2022–2024)David Sheridan · University of Edinburgh2 papers (2022–2023)S. Chakrabarti · University of Massachusetts Lowell2 papers (2015–2015)Michael R. Line · California Institute of Technology2 papers (2013–2021)Marc J. Kuchner · University of California, Santa Cruz2 papers (2015–2015)Stephen A. Harrison · Oxford Centre for Diabetes, Endocrinology and Metabolism2 papers (2022–2023)Yun‐Jung Choi · Jeonju National University of Education2 papers (2022–2023)James A. King · Alberta Health Services2 papers (2021–2022)